Spruce Biosciences, Inc.

SPRB Healthcare Biotechnology

Spruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023. In the quarter to June 2026, revenue fell 75.9%, EPS fell 90.9%, free cash flow fell 152.1% and total debt rose 427.2%, each against the same quarter a year earlier.

39.65 1.82 −4.39%
Market cap
$119.2M
P/E
0.0×
Fwd P/E
−2.3×
Dividend yield
—
F-score
n/a
Altman Z
36.60
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(167.93%) (109.24%) (148.85%) (105.98%)
ROA
(119.08%) (79.34%) (84.70%) (82.38%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(940.83%) (92.72%) (85.99%) (56.94%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(84.45) (43.45) (21.39) (17.60)
Free Cash Flow
(47.55) (33.33) (29.35) (42.78)
Capital Expenditures
— — (0.02) (0.15)
Other line items
Cash ROIC
(286.54%) (36.45%) (30.83%) (22.86%)
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Interest Coverage
(353.48) (405.70) (46.71) (26.63)
Operating CF/Net income
0.99 0.86 0.79 0.83
Depreciation/Fixed assets
0.00 0.00 0.00 0.00
Capex/Depreciation
0.00 0.00 (0.06) (0.17)
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(84.45) (43.45) (21.38) (17.53)
Capex per Share
0.00 0.00 (0.01) (0.06)
Capex to Sales
— — 0.00 0.00

Fold the line items

Columns are period end dates